

B.C. Centre for Excellence in HIV/AIDS Pharmacovigilance Initiative

Annual Report: 2022



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS



Providence Health Care
St. Paul's Hospital



Ministry of
Health

Disclaimer:

The BC Centre for Excellence in HIV/AIDS (BC-CfE) Pharmacovigilance Initiative receives reports of suspected adverse drug reactions, drug interactions and other adverse drug-related events associated with the use of antiretroviral medications for HIV treatment and prophylaxis. The information provided in this report summarizes post-marketing experience with antiretroviral therapy in persons who receive HIV medications through the BC-CfE Drug Treatment Program or Pre-Exposure Prophylaxis (PrEP) program. Reports of adverse drug-related events are voluntarily submitted by health care providers, patients and care-givers and are not systematically evaluated for accuracy or for the strength of evidence regarding the causal relationship between drug exposure and observed effect.

Information from reports of adverse drug-related events is stored in the BC-CfE Registry, a secure, computerized database. This database is updated on a regular basis. Figures and tables provided in the Annual Report represent the best estimates available at the time this document was published.

Figures and graphs presented in this document are best viewed in colour.

Statement of Confidentiality:

The personal information of patients and their health care providers is private and confidential. De-identified data are used for the purpose of drug safety surveillance in accordance with British Columbia Privacy legislation.

Report authors:

Ms. Katherine Lepik, BSc (Pharm), MSc
Research Coordinator, Pharmacovigilance
klepik@bccfe.ca

Dr. Rolando Barrios, MD, RCPSC
Principal Investigator, Pharmacovigilance
rbarrios@bccfe.ca

Pharmacovigilance Initiative
BC Centre for Excellence in HIV/AIDS
608-1081 Burrard Street
Vancouver, BC Canada V6Z 1Y6
Telephone: 604-806-8663
Fax: 604-806-9044
Website: <http://bccfe.ca/hiv-drug-safety>

Date: April 20, 2023

©BC Centre for Excellence in HIV/AIDS, 2023

Version date: July 1, 2023

Technical Support:

Ms. Olivia Hunt, Research Assistant
Mr. Justin Barath, Data Analyst

Table of Contents

Introduction	1
Acknowledgement	1
Conflict of interest declaration	1
Definitions and abbreviations	2
Reports of adverse drug-related events associated with antiretroviral medications	3
Table 1a. Adverse drug-related events associated with ART for HIV treatment – Five-year summary	3
Table 1b. Adverse drug-related events associated with ART for HIV treatment – 2022.....	3
Table 2a. Adverse drug-related events associated with ARVs for PrEP – Five-year summary	4
Table 2b. Adverse drug-related events associated with ARVs for PrEP – 2022	4
Adverse drug reactions (ADRs) associated with ART for HIV treatment and PrEP	5
Figure 1. Adverse drug reactions associated with ART for HIV treatment and prophylaxis (all drugs) – Five-year reporting patterns, by quarter	5
Adverse drug reaction (ADR) rates by antiretroviral drug class	6
Figure 2. Protease inhibitor ADR rates associated with ART for HIV treatment	7
Figure 3. Non-nucleoside reverse transcriptase inhibitor ADR rates associated with ART for HIV treatment.....	8
Figure 4. Integrase strand transfer inhibitors ADR rates associated with ART for HIV treatment.....	9
Figure 5. Nucleoside (-tide) reverse transcriptase inhibitors ADR rates associated with ART for HIV treatment or PrEP	10
Adverse Drug Reaction Rates by Symptom Category, associated with ART for HIV treatment	11
Figure 6a. Common ADRs by symptom category: >1.0 per 100 person-years exposure	12
Figure 6b. Uncommon ADRs by symptom category: 0.1-1.0 per 100 person-years exposure ...	13
Serious or Unexpected Adverse Drug Reactions Associated with ART for HIV Treatment or PrEP ...	14
Adverse Drug Reactions Associated with ART for HIV Treatment in Special Populations	15
Adverse drug reactions associated with ART for HIV treatment, by age category	15
Figure 7a. Total number of ART-treated patients in BC by age category.....	15
Figure 7b. Proportion of ADR reports in ART-treated persons by age	15
Adverse drug reactions associated with ART for HIV treatment, by biological sex	16
Figure 8a. Total number of ART-treated persons in BC by biological sex	16
Figure 8b. Proportion of ADR reports in ART-treated patients by biological sex.....	16
Drug Interactions Associated with ART for HIV Treatment	17
Figure 9. Antiretroviral drug interactions by ARV class	18
Figure 10. Antiretroviral drug interactions by interacting drug category	18
ART changes for prevention of adverse Drug reactions in persons receiving HIV treatment	19

How to report an adverse drug reaction to BC-CfE Pharmacovigilance..... 20

APPENDIX: Technical information 21

Introduction

The BC-CfE Pharmacovigilance Initiative collects, evaluates, and analyzes reports of drug toxicity and other adverse drug-related events associated with antiretroviral medications, and uses this information to understand and prevent drug-related problems.

Adverse drug reactions ("side-effects") to antiretroviral medications and interactions between antiretroviral medications and other drugs can affect patients' health and interfere with treatment success. All drugs are tested for safety before they are approved for sale in Canada; however, pre-marketing clinical trials cannot study enough patients to be able to detect adverse drug-related events that are rare, take a long time to develop, or occur more frequently in people with certain risk factors. These toxicities may be discovered after a drug is used in the general population

Ongoing monitoring of adverse drug-related events is required to detect unexpected toxicities as soon as possible, so that health care providers and patients can be warned of new safety concerns.

Acknowledgement

The Pharmacovigilance Initiative acknowledges with thanks the support provided by clerical staff, data analysts and programmers at the BC Centre for Excellence in HIV/AIDS, the staff of the St Paul's Hospital Ambulatory Pharmacy, and all those who report adverse drug-related events and Drug Treatment Program and PrEP program participants.

Conflict of Interest Declaration

The BC-CfE Pharmacovigilance Initiative does not receive pharmaceutical industry funding. The authors of this report have no conflicts of interest to declare within the past 3 years.

Definitions and abbreviations

The following definitions and abbreviations apply to terms used throughout this document. Terms that relate to a particular section of the report are defined within that section.

- **BC-CfE:** BC Centre for Excellence in HIV/AIDS
- **Adverse drug-related event:** Any untoward event associated with a medication. The BC-CfE captures events including (but not limited to) the following event categories:
 - **Adverse drug reaction (ADR):** A suspected adverse drug reaction (unintended, undesirable effect of an antiretroviral medication) attributed to one or more antiretroviral drugs. Includes events in which the medication is continued, dose adjusted or discontinued.
 - **ADR prevention:** Antiretroviral therapy is changed to prevent a potential adverse drug reaction.
 - **Drug interaction, symptomatic:** An adverse drug reaction resulting from a drug interaction between an antiretroviral medication and another drug.
 - **Drug interaction prevention:** Antiretroviral medication is discontinued or the dose is adjusted to prevent a potentially harmful drug interaction with another medication (no ADR occurred).
- **Adverse drug-related event information source:**
 - **Prescription:** All requests for new antiretroviral regimens for HIV treatment or prophylaxis must be reviewed and approved by the BC-CfE Drug Treatment Program. The 'Prescription Request' form includes a section for reporting adverse drug-related events.
 - Prescribers may also document adverse drug-related events on refill prescriptions for ongoing regimens.
 - **Therapy interruption alert/ Late refill notification:** BC-CfE mails Therapy Interruption Alerts to prescribers if the patient's refill history suggests a >2-month gap in therapy for HIV treatment or >3-month gap for PrEP. Forms include a section for reporting adverse drug-related events.
 - **Spontaneous report:** A report voluntarily submitted directly to the BC-CfE Pharmacovigilance Initiative.
- **ARV, antiretroviral drug:** Medications used to treat or prophylax against Human Immunodeficiency Virus (HIV) infection.
- **ART, antiretroviral therapy:** Combination of ARVs comprising the treatment regimen.
- **HIV-tx, HIV treatment:** Use of combination ART for the treatment of HIV infection (in HIV-positive persons).
- **PrEP, pre-exposure prophylaxis:** Use of certain ARVs to reduce the risk of acquiring new HIV infection.
- **Antiretroviral drug classes:**
 - NRTI: Nucleoside (-tide) reverse transcriptase inhibitor
 - NNRTI: Non-nucleoside reverse transcriptase inhibitor
 - PI: Protease inhibitor
 - INSTI: Integrase strand transfer inhibitor
 - PK enhancer: Pharmacokinetic enhancer ("booster")

Reports of adverse drug-related events associated with antiretroviral medications

Tables 1a-b and 2a-b summarize all reports of adverse drug-related events associated with antiretroviral use for HIV treatment and prophylaxis (PrEP), respectively. Overall reporting of events related to HIV treatment continued to decline in 2022, following a transient spike in preventative ART regimen changes in 2020 (See also: Figure 11). Reports of adverse drug-related events related to PrEP medication remained stable in 2022.

Table 1a. Adverse drug-related events associated with ART for HIV treatment – Five-year summary

Year	Number of patients receiving antiretroviral treatment	Adverse Drug-Related Event reports All categories, excluding duplicates	
		Total per year	Average per month
2018	7988	932	78
2019	8100	918	77
2020	8111	1044	87
2021	8150	742	62
2022	8225	531	44

Table 1b. Adverse drug-related events associated with ART for HIV treatment- 2022

Information Category	Reports including duplicates		Reports excluding duplicates	
	N=532	n (%)	N=531	n (%)
Event Type				
Adverse Drug Reaction	361	(68)	361	(68)
Adverse Drug Reaction Prevention	81	(15)	81	(15)
Drug Interaction Prevention	87	(16)	87	(16)
Drug Interaction, Symptomatic	3	(1)	2	(<1)
Information Source				
Prescription	529	(99)		*
Therapy Interruption Alert	1	(<1)		*
Spontaneous Report	2	(<1)		*
Reporter Type				
Physician	339	(64)		*
Pharmacist	188	(35)		*
Other Healthcare professional	4	(1)		*
Patient/ Consumer	1	(<1)		*

*Not applicable; multiple reporter or information source categories are possible for each event

Table 2a. Adverse drug-related events associated with ARVs for PrEP– Five-year summary

Year	Number of patients receiving antiretroviral treatment	Adverse Drug-Related Event reports All categories, excluding duplicates	
		Total per year	Average per month
2018	3186	24	2
2019	5008	57	5
2020	5334	34	3
2021	5901	39	3
2022	7359	51	4

Table 2b. Adverse drug-related events associated with ARVs for PrEP- 2022

Information category	Reports including duplicates		Reports excluding duplicates	
	N=52	n (%)	N=51	n (%)
Event Type				
Adverse Drug Reaction	47	(90)	46	(90)
Adverse Drug Reaction Prevention	4	(8)	4	(8)
Drug Interaction, Symptomatic	1	(2)	1	(2)
Information Source				
Prescription	40	(77)		*
Spontaneous Report	11	(21)		*
PrEP Interruption Alert	1	(2)		*
Reporter Type				
Physician	44	(85)		*
Pharmacist	1	(2)		*
Other Healthcare professional	7	(13)		*

*Not applicable; multiple reporter or information source categories are possible for each event

Adverse drug reactions (ADRs) associated with ART for HIV treatment and PrEP

As shown in **Figure 1**, there was a sharp drop-off and subsequent rebound in reporting rates of ADRs related to ART for HIV treatment in 2020 (COVID-19 pandemic-related disruptions), followed by a gradual decline in ADR rates, ongoing in 2022. ADR rates related to HIV prophylaxis have been relatively stable since the launch of the PrEP program in 2018.

Figure 1. Adverse drug reactions associated with ART for HIV treatment and prophylaxis (all drugs) – Five-year reporting patterns, by quarter




Figure 1 notes: Quarterly ADR rates in persons receiving ARVs for HIV treatment (HIV-tx) and prophylaxis (PrEP). Within each quarter (3-month period), the numerator is the number of ADR reports for ART-treated persons (excluding duplicates, events with unlikely causality and ART changes to prevent ADRs or drug interactions). The denominator is the total number of patient-years of ART exposure accrued during the quarter. Rates are expressed per 100 person-years of treatment. Error bars around each point display the 95% confidence interval, calculated by the Poisson method (using Byar approximation).

Adverse drug reaction (ADR) rates by antiretroviral drug class


This section focuses on ART for HIV treatment. Information regarding PrEP is included in the relevant sections.

Figures 2 to 5 display annual ADR rates over the past five years for the most commonly used ARVs. For each ARV, ADR rates are shown for all persons treated during the calendar year. See Appendix for details regarding calculation of rates.

2022 reporting year highlights:


- **Figure 2:** The use of PIs other than darunavir has declined substantially. Gastrointestinal adverse effects continue to be the most commonly reported PI-related ADRs.
- **Figure 3:** The use of older NNRTIs (nevirapine, efavirenz, etravirine) has declined substantially. Use of the newer NNRTI doravirine is increasing, with neuropsychiatric and gastrointestinal effects being the most commonly reported ADRs.
- **Figure 4:** The second generation INSTIs dolutegravir and bictegravir, account for the majority of INSTI new starts. Neuropsychiatric effects, gastrointestinal upset and unintentional weight gain remain the most commonly reported ADRs with these newer INSTIs.
- **Figure 5:** The shift in prescribing patterns from tenofovir DF to tenofovir AF continues. Among the NRTIs, tenofovir DF-associated renal and bone health-related toxicities continue to be the most commonly reported ADRs in HIV treatment clients. Weight gain is increasingly reported with tenofovir AF.

Figure 2. Protease inhibitor ADR rates associated with ART for HIV treatment




Number of adverse drug reaction (ADR) reports / Total patient-years drug exposure					
	2018	2019	2020	2021	2022
atazanavir	84/ 1120	54/ 947	34/ 747	34/ 738	23/ 509
darunavir	59/ 1347	57/ 1390	47/ 1286	52/ 1152	29/ 1288

Figure 3. Non-nucleoside reverse transcriptase inhibitor ADR rates associated with ART for HIV treatment




Number of adverse drug reaction (ADR) reports / Total patient-years drug exposure					
	2018	2019	2020	2021	2022
doravirine	No data	No data	Limited data	6/ 43	8/ 135
efavirenz	59/ 695	55/ 610	49/ 488	19/ 366	17/ 272
etravirine	7/ 232	<5/ 204	<5/ 177	<5/ 145	<5/ 115
nevirapine	5/ 709	12/ 617	6/ 427	5/ 337	5/ 278
rilpivirine	10/ 301	10/ 308	8/ 291	6/ 243	5/ 204

Figure 4. Integrase strand transfer inhibitor ADR rates associated with ART for HIV treatment



Number of adverse drug reaction (ADR) reports / Total patient-years drug exposure					
	2018	2019	2020	2021	2022
raltegravir	9/ 643	5/ 608	<5/ 512	<5/ 413	<5/ 331
elvitegravir	23/ 634	16/ 706	17/ 531	8/ 367	14/ 285
dolutegravir	90/ 2081	110/ 2464	83/ 2428	76/ 2382	81/ 2354
bictegravir	Limited data	<5/ 39	62/ 980	74/ 1939	85/ 2569

Figure 5. Nucleoside (-tide) reverse transcriptase inhibitor ADR rates associated with ART for HIV treatment or PrEP



Number of adverse drug reaction (ADR) reports / Total patient-years drug exposure					
	2018	2019	2020	2021	2022
abacavir	87/ 3025	83/ 3165	71/ 2951	82/ 2605	47/ 2196
tenofovir DF (HIV tx)	311/ 3287	285/ 3033	279/ 2307	146/ 1601	98/ 1172
tenofovir DF (PrEP)	22/ 1505	52/ 3025	33/ 3194	37/ 3379	46/ 4263
tenofovir AF	7/ 369	16/ 597	35/ 1523	54/ 2442	67/ 3034

Tenofovir AF, tenofovir alafenamide; Tenofovir DF, tenofovir disoproxil fumarate. ADR rates associated with use of tenofovir DF for HIV treatment (HIV-tx) and pre-exposure prophylaxis (PrEP) are reported separately.


Adverse Drug Reaction Rates by Symptom Category, associated with ART for HIV treatment

Figures 6a and 6b display annual ADR rates over the past five years by symptom category.

Symptom category summaries are organized by body system. For visual clarity, symptom categories are grouped into common (>1) and uncommon (0.1 to 1) ADR events per 100 person-years of ART exposure, displayed in Figures 6 a and b, respectively, and error bars are not displayed in the graphs.


See Appendix for details regarding calculation of rates.

2022 reporting year highlights: Although gastrointestinal, central nervous system, renal and musculoskeletal (bone health) concerns continue to be the most commonly reported ARV-associated ADRs (Figure 6a), ADR rates of these symptoms are declining, consistent with the overall decline in ADR rates. An increase in “general” side effects (Figure 6b) is driven by increasing reports of unintentional weight gain. Consistent with the literature, second generation INSTIs (dolutegravir, bictegravir) and the NRTI tenofovir AF are most commonly implicated in reports of unintentional weight gain.



Symptoms under these category headings may include the following. This is not a comprehensive list of all symptoms included:

- | | |
|---|--|
| Central nervous system/
Psychiatric (CNS/Psych): | Insomnia/ sleep disorder, nightmares/vivid dreams, headache, altered mood, altered mental status |
| Gastrointestinal (GI): | GI upset/ discomfort, nausea and/or vomiting, difficulty swallowing medication (“pill size”), diarrhea |
| Musculoskeletal: | Bone mineral loss (osteopenia, osteoporosis), myalgia/arthralgia |
| Renal: | Serum creatinine elevated/GFR low, proteinuria, nephrolithiasis, renal impairment (unspecified) |



Symptoms under these category headings may include the following. This is not a comprehensive list of all symptoms included:

- Endocrine/ Metabolic: Lipid abnormalities (e.g. elevated cholesterol), low serum phosphorus
- General: Unintentional weight gain/(loss), fatigue/malaise/low energy, general allergic reaction
- Hepatic: Hepatic transaminases (AST/ALT) elevated, cholelithiasis, abnormal liver function tests (unspecified)
- Isolated Hyperbilirubinemia: Hyperbilirubinemia ± jaundice
- Skin: Rash/hives, itching (no lesions)
- Other/ Unspecified: Other/ unspecified adverse reactions

Serious or unexpected adverse drug reactions associated with ART for HIV treatment or PrEP

In support of national and international drug safety monitoring programs, the BC-CfE Pharmacovigilance Initiative reports serious or unexpected adverse drug reactions to the Health Canada Vigilance Program, which in turn submits reports to the World Health Organization. Serious adverse drug reactions include those of grade IV severity (potentially life-threatening) and/or those resulting in hospital admission, prolongation of hospital stay or death. Unexpected reactions include clinically important events associated with newly marketed drugs, or rare adverse reactions associated with established drugs.

In 2022, there were a total of 410 adverse drug reaction reports received for HIV drug treatment and PrEP program clients combined (excluding duplicates, but including six reports assessed as "unlikely" causality). A total of 10/410 (2.4%) ADR reports were submitted to Health Canada. These included 6/363 (1.7%) of ADR reports for HIV treatment clients and 4/47 (8.5%) of reports received for PrEP clients. In total 4/410 (1.0%) were classified as serious ADRs.

Adverse drug reactions associated with ART for HIV treatment in special populations

Figures 7a-b and 8a-b display ADR reports stratified by age and sex, respectively. These analyses are limited to HIV treatment program participants, due to low numbers of seniors and females in the PrEP program.

Adverse drug reactions associated with ART for HIV treatment, by age category

In 2022, 16% of persons receiving ART for HIV treatment were seniors age ≥65 years. The proportion of seniors with a reported ARV ADR was similar to the proportion of younger persons with ADRs (4.6% vs. 4.3%, respectively), which was not a statistically significant difference (p = 0.567). ADRs most commonly reported in seniors were similar to the general population, with gastrointestinal, renal, musculoskeletal (bone health), and general (weight gain, fatigue) symptoms accounting for the majority of reports (listed in declining order of frequency).

Figure 7a. ART-treated persons in BC, by age category





Figure 7b. Proportion of ADR reports in ART-treated persons, stratified by age category



Adverse drug reactions associated with ART for HIV treatment, by biological sex

In 2022, 17% of the total ART-treated population were persons of female biological sex. The proportion of females with a reported ARV ADR was higher than for males (6.7% and 3.9%, respectively), which was a statistically significant difference ($p < 0.001$). ADRs most commonly reported in females were similar to the general population, with gastrointestinal, general (weight gain, fatigue), central nervous system (sleep disorder, headache), and musculoskeletal (bone health) symptoms accounting for the majority of reports (listed in declining order of frequency).

Figure 8a. ART-treated persons in BC, by biological sex





Figure 8b. Proportion of ADR reports in ART-treated persons by biological sex



Drug interactions associated with ART for HIV treatment

Figures 9 and 10 summarize antiretroviral drug interaction reporting patterns in 2022.

The pharmacokinetic enhancers ("boosters") cobicistat and ritonavir accounted for the majority of ART therapy changes related to drug interactions between HIV medications and other drugs.

Drug interactions between "boosters" and inhaled or injectable corticosteroids continue to be the most common drug interaction leading to adverse clinical effects (adrenal suppression). Drug interactions with gastrointestinal drugs (particularly gastric acid suppressing drugs) are declining secondary to declines in the use of susceptible ARVs (e.g. atazanavir). Interactions with cardiovascular drugs (e.g. anticoagulant and antiplatelet medications) are becoming more common, which might reflect evolving patterns of co-medication use in the aging cohort of persons living with HIV in BC.

Figure 9. Antiretroviral drug interactions by ARV class





Figure 10. Antiretroviral drug interactions by interacting drug category



Figures 9 and 10 notes: PK enhancer, Pharmacokinetic enhancer (“booster”) ritonavir or cobicistat; ARV-tx Patients, Drug Treatment Program participants receiving antiretrovirals for treatment of HIV; CNS, Central nervous system; NSAID, non-steroidal anti-inflammatory


ART changes for Prevention of Adverse Drug Reactions in persons receiving HIV treatment

Antiretroviral therapy changes for the purpose of preventing a potential ADR, such as reducing the long-term risk of renal injury, are documented as “ADR prevention”, and monitored separately from symptomatic ADRs. Reports of ADR prevention are only captured when the prescriber documents this intention on a request for ARV regimen change, and therefore the actual incidence of preventative regimen changes is likely underestimated.

Figure 11 shows the pattern of ART changes for ADR prevention in relation to reports of ADRs. In 2019 and 2020 there was a spike in preventative ARV regimen changes, associated with a shift to newer ARVs. Since 2021, there has been an overall decline in all ADR reports, including “ADR prevention”.

In 2022, the ARVs most commonly implicated in preventative changes are tenofovir DF (long term renal and bone health concerns), abacavir (cardiovascular risk reduction), and atazanavir (avoiding risk of renal stones).

Figure 11. Five-year reporting rates for ADRs and ART changes to prevent ADRs associated with ART for HIV treatment (all drugs)



How to report an Adverse Drug Reaction to BC-CfE Pharmacovigilance

Reports of suspected ADRs may be submitted to the BC-CfE Pharmacovigilance Initiative in several ways:

Any health care provider or person taking antiretroviral medication for HIV treatment or prophylaxis (PrEP) may report an antiretroviral ADR by completing an Antiretroviral Adverse Drug Reaction Report form. [Click to download ADR report form](#). Fax or mail the completed report to the address shown on the form.

Alternately, health care providers may choose to report suspected ADRs to the BC-CfE Pharmacovigilance Initiative in the following ways, instead of completing the ADR Report form:

Report on the HIV Drug Treatment Program or PrEP Program Prescription form:

For HIV Drug Treatment Program (DTP) clients, describe the suspected drugs and reaction in the "Reason(s) for medication change" section of the prescription request form. [Click here to access DTP documents](#)

For PrEP program clients, describe the suspected drugs and reaction on the prescription request or refill prescription form. [Click here to access PrEP documents](#)

Report on the HIV Drug Treatment Program or PrEP program therapy interruption/adherence Alert:

If a Drug Treatment Program or PrEP program client does not refill their prescribed ARV medications for more than two to three months after the expected refill date, a therapy interruption/adherence Alert is mailed to the client's health care provider to support continuity of care. The Alerts include the opportunity for healthcare providers to provide an update regarding the client's current treatment status, including an opportunity to report ADRs.

Report by telephone:

To submit a confidential adverse drug reaction report by telephone, contact the BC-CfE Pharmacovigilance Initiative Research Coordinator at 604-806-8663 (weekdays).

For more information regarding adverse reaction reporting and HIV medication safety, refer to the BC-CfE website: <http://bccfe.ca/hiv-drug-safety>

APPENDIX: Technical information

Analytical methods used in the preparation of this report are summarized below:

Unless otherwise specified, the inclusion and exclusion criteria for all Adverse Drug Reaction (ADR) analyses are as follows:

Include: Events categorized as ADR (including ADRs resulting from drug interactions), see Definitions.

Exclude: Duplicate reports of the same event, ADRs with a causality assessment of “unlikely” to be associated with ARV(s), and reports of therapy change to prevent ADRs or drug interactions.

ADR rates are reported without consideration for the duration of drug therapy prior to the ADR report, or the duration of symptoms prior to the ADR report date.

Figure 1: Calculation of overall ADR rates for HIV-treatment and PrEP patients. Within each quarter (3-month period), the numerator is the number of ADR reports for ART-treated persons. The denominator is the total number of patient-years of ART exposure accrued during the quarter. The resulting ADR rate is multiplied by 100 to give events per 100 person-years of treatment. Error bars around each point display the 95% confidence interval, calculated by the Poisson method.

Figure 2-5: Calculation of ADR rates, by antiretroviral drug. Within each calendar year, the numerator is the number of ADR reports specifying an adverse reaction attributed to the drug of interest. The denominator is the total number of patient years exposure to the drug, accrued during the time period. The resulting ADR rate is multiplied by 100 to give events per 100 person-years of treatment. Error bars around each point display the 95% confidence interval calculated by the Poisson method.

Figures 6a-b: Calculation of ADR Rates by symptom category. ADR reports contribute data for each relevant clinical category once per person in the calendar year the ADR was reported.

ADR rates are calculated as follows: In each calendar year, the numerator is the number of ADR reports specifying an adverse reaction for the symptom class of interest. The denominator is the total number of patient-years exposure to antiretroviral therapy for treatment of HIV during the calendar year. The resulting RATE is multiplied by 100 to give events per 100 person-years of treatment. Error bars around each point display the 95% confidence interval calculated by the Poisson method.